TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigge

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but hi

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains su

Tempus joins as a second commercial laboratory partnership to support oncology-focused access within

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholde

AI infrastructure spending dominates markets as Apple, Amazon, Microsoft and semiconductor companies

Tempus AI Inc. (NASDAQ:TEM) shares are trading lower on Friday as traders digest post-earnings reset

Tempus AI climbs 6.6% after its second-quarter loss narrows, revenues beat estimates and 2026 sales

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan,

Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed i

Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimat

Tempus AI (NASDAQ:TEM) reported second-quarter financial results Thursday after market close.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o

AI's next winners may emerge from an overlooked part of the market. See how three software companies

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo

TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deal

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to W

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat i

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holdin

Growth and chip stocks led a mixed Wall Street tape Monday as the S&P 500 and Nasdaq 100 rose wh

Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD

Bristol Myers Squibb adopts NVIDIA DGX SuperPOD to train next-gen AI models and accelerate drug disc

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal dat

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price t

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de

Nancy Pelosi has added stock or options in nine different companies since the start of 2025. A look

Dell beats massive estimates, IBM launches $5B Project Lightwell, CrowdStrike expands cyber insuranc

Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fue

Cathie Wood's Ark Invest bought Tempus AI shares while trimming Meta, signaling a shift toward m